// App-Quantinova.ai

PO‐091 : Total dose but not combination of Bortezomib regimen influences outcomes in multiple myeloma

Researchers

Presenter

  • A Srinivasan

Principal Investigators

  • F Djebbari

  • F Panitsas

  • G Vallance

  • M Sultanova

  • J Kothari

  • K Ramasamy

Medical Centers

  • Haematology, Oxford University Hospitals, Oxford,United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Bortezomib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved